Adjusted EBITDA came in at EUR 393 million, including a negative currency impact of EUR 24 million. Operating cash flow improved significantly to EUR 234 million, compared to EUR 151 million in the same period last year. For the first half of 2025, adjusted EBITDA reached €750 million (H1 2024: EUR 763 million). A key strategic move was the signing of a binding agreement to sell Akzo Nobel India to the JSW Group, with completion expected in Q4 2025. The planned sale of Akzo Nobel India marks the beginning of our portfolio optimisation efforts.”The company maintains its guidance and expects adjusted EBITDA to exceed EUR 1.48 billion for the full year 2025 (at constant currencies).